The goal for the Expanded Access Program is to address an unmet medical need by providing early access to melflufen treatment for RRMM patients who meet all eligibility criteria.
This trial is currently open and accepting patients.
This expanded access protocol is being made available for up to 200 eligible patients.
This expanded access protocol is organized in 28 day cycles. Patients will receive:
Patients may continue to participate in the protocol as long as their myeloma doesn’t get worse, if they don’t experience bad side effects or transfer of the patient to the commercial drug following FDA approval or 90 days following approval, whichever comes first.
Patients may be eligible to receive financial assistance for travel and lodging purposes through Oncopeptides’ partner, Lazarex Cancer Foundation. Patients can find more details on the Lazarex PATH (Patient Access Transforming Health) Program by clicking here or in the Resources section below.
Enrollment: 200 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
The Expanded Access Program is not limited to the sites that you find listed below. If you are a patient and do not see your center listed as a participating site below, please contact SparkCures at (888) 828-2206 for additional assistance.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message